Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1368.75
-5.80 (-0.42%)
< Home < Back

Dr. Reddy’s Laboratories informs about media release

Date: 21-03-2026
Dr. Reddy’s Laboratories has informed that it enclosed a Press Release titled “Dr. Reddy’s Laboratories announces launch of India’s first DCGI-approved Semaglutide injection ‘Obeda®’ for Type 2 Diabetes.’

The above information is a part of company’s filings submitted to BSE.